- relapsing patients, for whom an initial period of PRN1008 monotherapy, or combination therapy with any of low dose corticosteroid (≤ 10 mg/day), azathioprine, mycophenolate mofetil, sulfasalazine and dapsone, is judged clinically acceptable, provided cessation of azathioprine, mycophenolate mofetil, sulfasalazine, and dapsone within two to four weeks is anticipated